i&i Biotech Fund I SCSp (i&i Bio, LU)

https://www.inibio.eu

i&i Bio is a Luxembourg-based venture capital firm that invests in innovative European Life Sciences companies focused on drug discoveries, medical devices, diagnostics, and digital health. The Fund was created thanks to the cooperation of the biotech incubator i&i Prague and the European Investment Fund. With over €45M under management, i&i Bio plans to invest in about 20 early-stage companies. i&i Bio is led by an experienced team of professionals with backgrounds in private equity, healthcare and venture capital supporting entrepreneurs on their journey to global success. Thanks to the close cooperation with the fund’s sponsor, the biotech academic incubator i&i Prague, i&i Bio is supporting and advancing transformative Central European technology companies. i&i Bio is supported by an investment from the EIF, with the support of: > lnnovFin Equity, with the financial backing of the European Union under Horizon 2020 FinancialInstruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing; and > the Pan-European Guarantee Fund (EGF), implemented by the EIF with the financial support of the Participating Member States. The objective of EGF is to respond to the economic impact of the COVID-19 pandemic by ensuring that companies in the Participating Member States have sufficient short-term liquidity available to weather the crisis and are able to continue their growth and development in the medium to long-term. *

	Start	2022-02-10 existent
	Group	i&i (Group)
	Industry	venture capital
	Industry 2	LIFE SCIENCES

	Region	Luxembourg (cl=5)
	Country	Luxembourg
	City	n. a. Luxembourg
		Address record changed: 2022-11-09

Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	45,000,000 (capital under management (2022) 2022-11-02)

		* Document for »About Section«: Enzyre B.V.. (11/2/22). "Press Release: Enzyre Closes Series A Financing Round of EUR 12M to Advance Pioneering Diagnostic Technology Platform for Hemophilia Patients". Nijmegen.

		Record changed: 2024-02-12